AnodyneWiki

Budesonide

Budesonide
Budesonide
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass430.50 g/mol [1]
AppearanceCrystals [1]
Melting point226°C [1]
Boiling point599.7 [1]
SolubilityPractically insoluble in water [1]
Predicted LogP2.5 [1]
Structural Identifiers
[]
Molecular formulaC25H34O6
IUPAC name(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
SMILESCCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
InChIInChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
InChIKeyVOVIALXJUBGFJZ-KWVAZRHASA-N
CAS number51333-22-3
UNIIQ3OKS62Q6X
PubChem CID5281004
Pharmacokinetics[]
Elimination half-life2.0-3.6 hours
MetabolismLiver CYP3A4
ExcretionUrine, feces
Routes of administrationBy mouth, nasal, tracheal, rectal, inhalation

Budesonide (also known as Entocort, Preferid, Rhinocort Aqua, Pulmicort, Entocort EC, Uceris, Rhinocort, Pulmicort Respules, Pulmicort Flexhaler or Budenofalk).

Chemistry

 []

Budesonide matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days. Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10. Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive. High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

metabolism / inhibition / induction180
shared target1

Medical side effects []

216 side effects listed on drug labels in (budesonide).

  • Cushing's syndrome
  • Respiratory tract infection
  • Headache
  • Acne
  • Hyperhidrosis
  • Otitis media
  • Rhinitis
  • Nausea
  • Cushingoid
  • Nasopharyngitis
  • Contusion
  • Oedema peripheral
  • Joint swelling
  • Dizziness
  • Syncope
  • Lightheadedness
  • Back pain
  • Insomnia
  • Dyspepsia
  • Flatulence
  • Arthralgia
  • Musculoskeletal discomfort
  • Myalgia
  • Cough
  • Cough increased
  • Gastroenteritis
  • Asthenia
  • Fatigue
  • Candida infection
  • Oral candidiasis
  • Candida albicans infection
  • Diarrhoea
  • Muscle spasms
  • Viral infection
  • Vomiting
  • Ear infection
  • Abdominal pain upper
  • Epigastric pain
  • Hirsutism
  • Pain
  • Ache
  • Blood cortisol decreased
  • Abdominal pain
  • Gastrointestinal pain
  • Epistaxis
  • Dysphonia
  • Vision blurred
  • Nasal congestion
  • Viral upper respiratory tract infection
  • Rhinitis allergic
  • Conjunctivitis
  • Dermatitis
  • Rash
  • Menstrual disorder
  • Nasal discomfort
  • Abdominal distension
  • Viral diarrhoea
  • Lipohypertrophy
  • Pharyngitis
  • Fluid retention
  • Constipation
  • Urinary tract infection
  • Flushing
  • Hyperadrenocorticism
  • Anaphylactic shock
  • Angioedema
  • Anosmia
  • Anxiety
  • Mental disorder
  • Bronchospasm
  • Bronchoconstriction
  • Bronchitis
  • Infection
  • Connective tissue disorder
  • Dermatitis contact
  • Endocrine disorder
  • Eye disorder
  • Congenital eye disorder
  • Body temperature increased
  • Glaucoma
  • Cardiac disorder
  • Hypersensitivity
  • Type IV hypersensitivity reaction
  • Immune system disorder
  • Irritability
  • Mediastinal disorder
  • Necrosis ischaemic
  • Osteonecrosis
  • Nervous system disorder
  • Nervousness
  • Tension
  • Osteoporosis
  • Palpitations
  • Pharyngeal disorder
  • Pruritus
  • Benign intracranial hypertension
  • Psychotic disorder
  • Sinusitis
  • Swelling
  • Urticaria
  • Wheezing
  • Agitation
  • Hyperkinesia
  • Mood swings
  • Affect lability
  • Cataract
  • Growth retardation
  • Skin irritation
  • Skin disorder
  • Psychiatric symptom
  • Intraocular pressure increased
  • Nasal septum perforation
  • Oropharyngeal discomfort
  • Oropharyngeal pain
  • Throat irritation
  • Abscess
  • Adrenal insufficiency
  • Alopecia
  • Amnesia
  • Anaemia
  • Decreased appetite
  • Appetite absent
  • Anorectal disorder
  • Arthritis
  • Arthritis aggravated
  • Coagulopathy
  • Bone disorder
  • Breast disorder
  • Neck pain
  • Chest pain
  • Allergic granulomatous angiitis
  • Leukocytoclastic vasculitis
  • Confusional state
  • Feeling abnormal
  • Malaise
  • Dysgeusia
  • Bad taste
  • Dyspnoea
  • Dysuria
  • Ear pain
  • Ecchymosis
  • Eczema
  • Enteritis
  • Eye infection
  • Multiple fractures
  • Fracture
  • Gastrointestinal disorder
  • Glossitis
  • Haematuria
  • Haemorrhage
  • Haemoglobin
  • Haemorrhoids
  • Herpes simplex
  • Hypertension
  • Hypokalaemia
  • Influenza
  • Intestinal obstruction
  • Leukocytosis
  • Metrorrhagia
  • Hypertonia
  • Nocturia
  • Paraesthesia
  • Purpura
  • Vascular purpura
  • Pyuria
  • Sneezing
  • Gastric disorder
  • Stridor
  • Shock
  • Loss of consciousness
  • Tachycardia
  • Thirst
  • Tooth disorder
  • Tremor
  • Ulcer
  • Pollakiuria
  • Urethral disorder
  • Urinary tract disorder
  • Angiopathy
  • Vertigo
  • Visual impairment
  • Abnormal vision
  • Weight increased
  • Dry mouth
  • Rash pustular
  • Drug withdrawal syndrome
  • Migraine
  • Tongue disorder
  • Tongue oedema
  • Red blood cell sedimentation rate increased
  • Impaired healing
  • Blood alkaline phosphatase increased
  • Skin striae
  • Malnutrition
  • Scab
  • Discomfort
  • Ill-defined disorder
  • Hair growth abnormal
  • Increased appetite
  • Tenderness
  • Gravitational oedema
  • Lymphadenopathy
  • Bronchospasm paradoxical
  • Secondary adrenocortical insufficiency
  • Gastrointestinal fistula
  • Face oedema
  • Sexual dysfunction
  • C-reactive protein increased
  • Ear pruritus
  • Infestation
  • Sleep disorder
  • Crohn's disease
  • Local reaction
  • Oropharyngeal candidiasis
  • Procedural complication
  • Somnolence

Indications

  • Asthma
  • Colitis ulcerative
  • Crohn's disease
  • Croup
  • Inflammation
  • Nasal polyps
  • Perennial allergic rhinitis
  • Rhinitis perennial
  • Seasonal allergy
  • Vasomotor rhinitis

 []

  • Australia: Budesonide is a S2 / S4.[3]
  • Canada: Budesonide is Prescription only.[4]
  • United Kingdom: Budesonide is Prescription only.
  • United States: Budesonide is a OTC / Prescription only.[5][6][7]
  • European Union: Budesonide is Prescription only.[8]

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 5281004, Budesonide. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5281004
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Budesonide. UNII: Q3OKS62Q6X. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/Q3OKS62Q6X
  3. Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025. Therapeutic Goods Administration (TGA). May 2025. https://www.legislation.gov.au/F2025L00599/asmade/2025-05-28/text/original/pdf
  4. Regulatory Decision Summary - Uceris. Health Canada. 23 October 2014. https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00675
  5. Tarpeyo- budesonide capsule, delayed release. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=938cada4-d6bf-4252-836f-dd40f9eadb4d
  6. Pulmicort Flexhaler- budesonide aerosol, powder. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54234b7d-3bcc-4809-1881-1d21484856a0
  7. Eohilia- budesonide suspension. DailyMed. 9 February 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56f2023a-69b2-4470-b4ad-af7ec1be527a
  8. Jorveza EPAR. European Medicines Agency (EMA). 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/jorveza

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 13:22:25
drugspromissing (no DrugsPRO reagent data)2026-11-20 13:22:21
erowidmissing (no Erowid substance of that name)2026-11-20 13:22:21
gsrsok2026-11-20 13:22:21
hmdbmissing (hmdb.ca refused automated access to HMDB0015353)2026-11-20 13:22:21
keggok2026-11-20 13:22:23
pubchemok2026-11-20 13:22:17
redditmissing (no r/tripreports posts mention it)2026-11-20 13:22:21
siderok2026-11-20 13:22:21
structureok2026-11-20 13:22:21
wikipediaok2026-11-20 13:22:21